Biotech News
GSK to showcase long-term outcomes and pipeline expansion with latest oncology research at ASCO and EHA
GSK will present new data from its expanding oncology portfolio and pipeline at ASCO and EHA.
Open original release
Related news
GSKGSK plc2026-07-28 12:00 EST
GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026
GSKGSK plc2026-05-06 12:00 EST
GSK presents latest respiratory research to advance patient care at ATS 2026
BNTXBioNTech2026-05-22 09:00 EST
BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting
BMYBMYBristol-Myers Squibb Company2026-05-21 21:01 EST
Bristol Myers Squibb to Unveil New Data at ASCO® 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline
KURAKura Oncology2026-05-12 13:40 EST
Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress
KURAKura Oncology2026-05-19 20:02 EST
Kura Oncology to Present at TD Cowen 7th Annual Oncology Innovation Summit
BMEABiomea Fusion2026-06-03 12:00 EST
Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity
BCRXBioCryst Pharmaceuticals2026-05-27 11:00 EST
BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting
GSK plc
GSK is a global biopharmaceutical company with meaningful exposure to vaccines, respiratory medicines, immunology, and infectious disease. The company has been reshaping its portfolio around stronger innovation and higher-growth specialty products.
Recent company news
GSKGSK plc2026-07-28 12:05 EST
GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK
GSKGSK plc2026-07-28 12:00 EST
GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026
GSKGSK plc2026-07-28 11:00 EST
GSK’s licensor Hansoh Pharma announces positive results from a second phase III trial for Ris-Rez in China
GSKGSK plc2026-07-27 14:55 EST
ViiV Healthcare’s 2-drug regimen Dovato is as effective as 3-drug regimen Biktarvy in first-of-its-kind head-to-head study in treatment-naïve adults living with HIV
GSKGSK plc2026-07-22 11:21 EST
Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer
Stock data
- Close
- 51.98 USD
- Market cap
- 98.26B USD
- Exchange
- NYSE
- Sector
- Vaccines, Biopharma, Gene Therapy, Antibody Drugs, Small Molecule Drugs, Nucleic Acid Drugs
- Location
- United States